Read a selection of publications and posters from Aplagon’s scientists.
Publications
Kotimaa J, Artero Rezola M, Jouppila A, Lassila R, Meri S. Interactions of dual antiplatelet-anticoagulant (APAC) with C1q and FH modulate complement activation on injured cells. Blood Vessels, Thrombosis & Hemostasis. 2026; 100150. https://doi.org/10.
Bagoly et al. Escalating doses of intravenous APAC demonstrate antithrombotic effect in pigs. Thrombosis Journal volume 23, Article number: 57 (2025). read more
Jouppila et al. Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics. Thromb Res. June 2025; 250, 109318. https://doi.org/10.1016/j.thromres.2025.109318. read more
Matrai AA, Varga A, Bedocs-Barath B, Vanyolos E, Orban-Kalmandi R, Loczi L, Bagoly Z, Jouppila A, Lassila R, Nemeth N, Deak A. Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model. J Thromb Thrombolysis, 2024, 57(8):1329-1338. Doi:10.1007/s11239-024-03040-8. read more
Bot I, Delfos L, Hemme E, et al. Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe-/- mice. Atherosclerosis. 2024;397:118567. https://doi.org/10.1016/j.atherosclerosis.2024.118567. read more
Denorme F, Frösen J, Jouppila A, et al. Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia-reperfusion injury in a mouse model of temporary middle cerebral artery occlusion-implications for neurovascular procedures. Acta Neurochir (Wien). 2024;166(1):137. https://doi.org/10.1007/s00701-024-06017-x. read more
Bonetti NR, Jouppila AS, Saeedi Saravi SS, et al. Intravenously administered APAC, a dual AntiPlatelet AntiCoagulant, targets arterial injury site to inhibit platelet thrombus formation and tissue factor activity in mice. Thromb Res. 2023;228:163-171. read more
Kohli S, Shahzad K, Jouppila A, Holthöfer H, Isermann B, Lassila R. Thrombosis and Inflammation-A Dynamic Interplay and the Role of Glycosaminoglycans and Activated Protein C. Front Cardiovasc Med. 2022;9:866751. Published 2022 Mar 31. read more
Winzely, Maximilian; Jouppila, Annukka; Ramer, Georg; Lux, Laurin; Lendl, Bernhard; Barreiro, Karina; Lassila, Riitta; Friedbacher, Gernot. AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan). Analytical and Bioanalytical Chemistry. 2022;414(2):1029-1038; 10.1007/s00216-021-03765-y. read more
Craige, Simon; Jouppila, Annukka; Humphries, Bob; Lassila, Riitta. Safety and Functional Pharmacokinetic Profile of APAC, a Novel Intravascular Antiplatelet and Anticoagulant. Journal of Cardiovascular Pharmacology. September 2021; 78(3):453-462. read more
Pepe, Martino; Peruzzi, Mariangela; Biondi-Zoccai, Giuseppe; Giordano, Arturo. Antithrombotic Therapy for Vascular Disease and Intervention: The Best Is Yet to Come? Journal of Cardiovascular Pharmacology. September 2021; 78(3):334-335. read more
Barreiro K, Tulamo R, Jouppila A, Albäck A, Lassila R. Novel Locally Acting Dual Antiplatelet and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an Experimental Porcine Model. Eur J Vasc Endovasc Surg. 2019, Dec; 58(6):903-911. read more
Vögtle T, Sharma S, Mori J, et al. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. eLife 2019, 8: 22 Aug, 46840. read more
Chen J, Verni CC, Jouppila A, Lassila R, Diamond SL. Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation. Thromb Res. 2018 Jul 25; 169:143-151. read more
Tuuminen R, Jouppila A, Salvail D, Laurent C E, Benoit M C, Syrjälä S, Helin H, Lemström K, Lassila R. Dual antiplatelet and anticoagulant APAC prevents experimental ischemia-reperfusion-induced acute kidney injury. Clin Exp Nephrol. 2017 Jun;21(3):436-445. read more
Lassila R, Jouppila A. Mast cell-derived heparin proteoglycans as a model for a local antithrombotic. Semin Thromb Hemost. 2014 Nov;40(8):837-44. read more
Olsson E, Asko-Seljavaara S, Lassila R. Topically administered macromolecular heparin proteoglycans effectively inhibit thrombus growth in microvascular anastomoses. Thromb Haemost, 2002, 87;245-51. read more
Kauhanen P, Kovanen PT, Lassila R. Coimmobilized native macromolecular heparin proteoglycans strongly inhibit platelet interactions under flowing blood. Arterioscler Thromb Vasc Biol, 2000, 20:e113-e119. read more
Kauhanen P, Kovanen PT, Reunala T, Lassila R. Effects of cutaneous mast cells on bleeding time and coagulation activation at the site of platelet plug formation. Thromb Haemost, 1998, 79:843-7. read more
Lassila R, Lindstedt K, Kovanen PT. Native macromolecular heparin proteoglycans exocytosed from stimulated rat serosal mast cells strongly inhibit platelet-collagen interactions. Arterioscler Thromb Vasc Biol, 1997, 17:3578-87. read more
Congress abstracts
All posters below are available on request.
Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2025
Mehta et al. Dose escalation effects of intravenous APAC, a heparin proteoglycan mimic, in healthy participants. view poster
2025 International Society of Thrombosis and Hemostasis (ISTH) Congress
Mehta et al. Dose escalation effects of intravenous APAC, a heparin proteoglycan mimic, in healthy participants. view poster
2024 International Society of Thrombosis and Hemostasis (ISTH) Congress
Fatima S, Khawaja H, Ambreen S, Gupta A, Kohli S, Elwakiel A, Jouppila A, Lassila R, Isermann B, Shahzad K. Antiplatelet and anticoagulant (APAC) compound restricts thromboinflammation and maintains cardiac function following myocardial injury. OC 79.3 26 Jun, 2024; 102503, p.240. https://doi.org/10.1016/j.rpth.2024.102503. view abstract
Jouppila A, Mattila T, Lemponen M, Lassila R. APAC, a heparin proteoglycan mimic, is a potent von Willebrand Factor-mediated antithrombotic over collagen in a microfluidic blood perfusion system under high shear rate. PB1165. 25 Jun, 2024; 102504, p.191. https://doi.org/10.1016/j.rpth.2024.102504. view abstract
2023 International Society of Thrombosis and Hemostasis (ISTH) Congress
Fatima S, Ambreen S, Kohli S, Lassila R, Isermann B, Shahzad K. Antiplatelet and anticoagulant compound (APAC) restricts thromboinflammation to ameliorates myocardial ischemia reperfusion injury. OC 62.5. 27 Jun, 2023; 392396 view abstract
Bagoly Z, Jouppila A, Orbán-Kálmándi R, Lóczi L, Bomberák D, Deák A, Mátrai Á, Németh N, Lassila R. Comprehensive coagulation activity assessments of escalating doses of intravenous APAC, a heparin proteoglycan mimic, in pigs. PB 1082 Jun 27, 2023;382156 view abstract
2022 International Society of Thrombosis and Hemostasis (ISTH) Congress
Kotimaa J, Rezola M, Jouppila A, Meri S, Lassila R. Interaction of Antiplatelet and Anticoagulant APAC with Complement Proteins Attenuates Complement Activation via C1q and Factor H. PB0739. 11 Jul, 2022; 359839 read more
Bot I, Jouppila A, Delfos L, Hemme E, Kovanen P, Lassila R. APAC Treatment Limits Collar-induced Carotid Atherosclerotic Plaque Development in ApoE-/- Mice. OC 18.5. 10 Jul; 2022;359344 read more
2021 International Society of Thrombosis and Hemostasis (ISTH) Congress
Nevzorov I, Jouppila A, Lassila R. A Novel Dual AntiPlatelet and AntiCoagulant APAC: Interaction Between Platelet Factor 4 (PF4) and APAC Decreases Functional Activity. PB 0880. 17 Jul, 2021; 327000 view abstract
2019 International Society of Thrombosis and Hemostasis (ISTH) Congress
R. Lassila, A. Jouppila. APAC, a dual AntiPlatelet and AntiCoagulant – towards a local vascular targeting antithrombotic. PB 1534. Jul 9, 2019; 264723 view abstract
Parry M, Jouppila A, Lassila R. APAC, a dual anticoagulant and antiplatelet, synergistically with acetylsalicylic acid inhibits collagen-induced platelet aggregation. PB 0431 7 Jul, 2019;263617 view abstract
2017 International Society of Thrombosis and Hemostasis (ISTH) Congress
K.A. Barreiro, A. Jouppila, R. Tulamo, A. Albäck, R. Lassila APAC, a Dual Antiplatelet and Anticoagulant Heparin Proteoglycan Mimetic, Integrates with Extravascular Matrix during Vascular Injury. PB 1629. (2017) Abstracts. Res Pract Thromb Haemost, 1: 1405. doi:10.1002/rth2.12012 view abstract
N.R. Bonetti, A. Jouppila, S. Gobbato, S. Stivala, G.G. Camici, R. Lassila and J.H. Beer. A Dual Antiplatelet (AP) and Anticoagulant (AC) Compound – APAC – Inhibits Collagen-induced Platelet Aggregation in Mice and Protects against Arterial Thrombosis. PB 082. (2017) Abstracts. Res Pract Thromb Haemost, 1: 349 – 350. doi:10.1002/rth2.12012 view abstract
A. Jouppila, M. Lemponen, K. Barreiro, R. Lassila APAC, a Dual Antiplatelet and Anticoagulant Attenuates Collagen-induced Platelet Aggregation and Fibrin Elasticity in Blood. PB 2204. (2017) Abstracts. Res Pract Thromb Haemost, 1: 1275. doi:10.1002/rth2.12012 view abstract
2016 Platelets 9th International Symposium
A. Jouppila, K. Barreiro, R. Tulamo, A. Albäck, and R. Lassila. APAC, a Dual Antiplatelet and Anticoagulant Heparin Proteoglycan Mimetic Targets Von Willebrand Factor in Injured Vessel Wall view poster
2015 International Society of Thrombosis and Hemostasis (ISTH) Congress
Jouppila A, Benoit M-C, Laurent CE, Salvail D and Lassila R. Pharmacokinetics and pharmacodynamics of APAC, a dual novel anticoagulant and antiplatelet heparin complex. PO081-WED. (2015) J Thromb and Haemost, 13 (Suppl. 2): 783 http://doi.org/10.1111/jth.12993 view abstract
